You are here
Azevan Pharmaceuticals Inc
UEI: VHSKTKSAY2S1
# of Employees: 7
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Advancing SRX246 to Commericialization
Amount: $3,190,881.00PROJECT SUMMARY/ABSTRACTSRX246, a first-in-class, orally bioavailable, CNS-active vasopressin 1a receptor antagonist, recently was tested in an Exploratory Phase 2 clinical trial, “Safety, Tolerabil ...
SBIRPhase II2020Department of Health and Human Services National Institutes of Health -
A New Drug for the Treatment of Traumatic Brain Injury
Amount: $501,472.00Project Summary AbstractTraumatic Brain InjuryTBIcontributes to a third of injury related deaths in the US and is among the leading causes of death and disability in people underand overRecent statist ...
SBIRPhase I2019Department of Health and Human Services National Institutes of Health -
Tolerability of SRX246 in Huntington's Disease Patients
Amount: $4,519,924.00DESCRIPTIONprovided by applicantHuntington s DiseaseHDis an inherited disease that results from expansion of a trinucleotideCAGcytosine adenine guaninerepeat that encodes a polyglutamine tract in the ...
SBIRPhase II2016Department of Health and Human Services National Institutes of Health -
Tolerability of SRX246 in Huntington's Disease Patients
Amount: $3,329,539.00DESCRIPTION provided by applicant Huntingtonandapos s Disease HD is an inherited disease that results from expansion of a trinucleotide CAG cytosine adenine guanine repeat that encodes a poly ...
SBIRPhase I2015Department of Health and Human Services National Institutes of Health -
Screening New Therapeutics for the Treatment of Post Traumatic Stress Disorder
Amount: $141,071.00DESCRIPTION (provided by applicant): Project Summary/Abstract Post-traumatic Stress Disorder (PTSD) is recognized by the NIMH, the Department of Defense, and the Veterans' Administration as ...
STTRPhase I2011Department of Health and Human Services National Institutes of Health -
New Drugs for Stress-related Affective Illness
Amount: $1,794,075.00DESCRIPTION (provided by applicant): Vasopressin (AVP) antagonists represent a novel therapeutic class for the treatment of depression. The potential utility of these compounds has emerged from observ ...
SBIRPhase II2011Department of Health and Human Services National Institutes of Health -
New Drugs for Stress-related Affective Illness
Amount: $349,195.00DESCRIPTION (provided by applicant): Vasopressin (AVP) antagonists represent a novel therapeutic class for the treatment of depression. The potential utility of these compounds has emerged from observ ...
SBIRPhase I2010Department of Health and Human Services National Institutes of Health -
A Potential New Drug for Depression
Amount: $226,385.00DESCRIPTION (provided by applicant): A Potential New Drug for Depression, an active SBIR Phase IIa award. The requested funds will allow additional characterization studies of three newly discovered ...
SBIRPhase II2009Department of Health and Human Services National Institutes of Health -
TREATING SELF-ABUSE IN AUTISM AND MENTAL RETARDATION
Amount: $0.00Serenix Pharmaceuticals LLC (SPL) will develop drugs to treat impulsivity, violence and self-injurious behavior in patients with autism, Tourette's syndrome, and mental retardation. These drugs, terme ...
STTRPhase I2002Department of Health and Human Services National Institutes of Health -
A NEW DRUG FOR DEPRESSION
Amount: $100,000.00Long Term Goals: Serenix Pharmaceuticals (SP) will develop drugs for the treatment of CNS disorders. Strategy: SP acquired a series of vasopressin receptor antagonists from Eli Lilly and Company and h ...
SBIRPhase I2002Department of Health and Human Services National Institutes of Health